In routine pathological studies, breast cancer subtypes are classified using four immunohistochemistry (IHC) markers (ER, PR, HER2, and Ki-67) to replace the gene subtype while designing treatments, predicting patient prognosis, and even enrolling in clinical trials. Here, ESR1 is linked to breast cancer.